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ABSTRACT
Many cancer therapies operate by inducing double-strand breaks (DSBs) in cancer cells, however
treatment-resistant cells rapidly initiate mechanisms to repair damage enabling survival. While the
DNA repair mechanisms responsible for cancer cell survival following DNA damaging treatments
are becoming better understood, less is known about the role of the epigenome in this process.
Using prostate cancer cell lines with differing sensitivities to radiation treatment, we analysed the
DNA methylation profiles prior to and following a single dose of radiotherapy (RT) using the
Illumina Infinium HumanMethylation450 BeadChip platform. DSB formation and repair, in the
absence and presence of the DNA hypomethylating agent, 5-azacytidine (5-AzaC), were also
investigated using γH2A.X immunofluorescence staining. Here we demonstrate that DNA methy-
lation is generally stable following a single dose of RT; however, a small number of CpG sites are
stably altered up to 14 d following exposure. While the radioresistant and radiosensitive cells
displayed distinct basal DNA methylation profiles, their susceptibility to DNA damage appeared
similar demonstrating that basal DNA methylation has a limited influence on DSB induction at the
regions examined. Recovery from DSB induction was also similar between these cells. Treatment
with 5-AzaC did not sensitize resistant cells to DNA damage, but rather delayed recruitment of
phosphorylated BRCA1 (S1423) and repair of DSBs. These results highlight that stable epigenetic
changes are possible following a single dose of RT and may have significant clinical implications
for cancer treatment involving recurrent or fractionated dosing regimens.
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Introduction
Numerous cancer therapies rely on inducing double-
strand breaks (DSBs) in cancer cells to induce cell
death. However, in cases of treatment resistance,
a subpopulation of cells is capable of repairing geno-
mic lesions to survive treatment either via non-
homologous end joining or homologous recombina-
tion.While a clear picture for the role of DNA repair
proteins in this process has emerged (reviewed in
[1]), there is less clarity regarding the epigenetic
mechanisms involved. In particular, the role of the
basal epigenetic environment in influencing suscept-
ibility to DNA damage, as well as changes to the
epigenetic landscape following DNA damage, are
not well characterized. The epigenetic changes in
response to DNA damage are also key to under-
standing whether DNA methylation changes that
result from radiotherapy (RT) may contribute to
treatment resistance.
The chromatin landscape within tumour cells has
the potential to influence whether they are suscepti-
ble to DNA damage caused by RT (reviewed in [2]).
It is conceivable that DNA in a loosely packed chro-
matin environment might be more susceptible to
DNA damage than in a tightly condensed hetero-
chromatin state. Conversely, damaged DNA in
euchromatin could be expected to bemore accessible
to DNA repair proteins than when present in hetero-
chromatin [3]. Following signalling to recruit DNA
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repair proteins, the region surrounding the lesion
must be remodelled to enable access. Following
DNA repair, the local chromatin environment
should ideally be restored to its original structure
and epigenetic state. Therefore, an adaptive epige-
netic response to DNA damaging treatments may
have important implications for future response to
treatment. In this context, evidence is emerging for
heritable epigenetic silencing in regions surrounding
DSBs [4–6] that could in turn influence susceptibility
to DNA damage and treatment success. This is par-
ticularly important in the case of current cancer
treatment regimens as patients receive repeated frac-
tionated doses of RT and/or recurrent infusions of
chemotherapeutic agents.
The most frequently characterized epigenetic
alteration triggered by DNA damage is the forma-
tion of γH2A.X foci. These foci form when the
histone variant H2A.X is phosphorylated at serine
139 in response to DSBs [7] and appears impor-
tant for recruitment of the relevant repair proteins.
γH2A.X marks chromatin domains impacted by
DNA damage and helps to initiate checkpoint-
mediated arrest, spreading over large domains to
mark the region for repair. However, the remodel-
ling events and modifications to the epigenome
prior to and following DSB repair are yet to be
elucidated. DNA methylation is the most widely
studied epigenetic modification and has been asso-
ciated with RT treatment resistance, with
demethylating agents improving therapeutic sensi-
tivity of tumour cells [8–12]. Importantly, basal
methylation status may provide clinically relevant
predictors for response to treatment. DNA methy-
lation may limit RT-induced DNA damage due to
heterochromatin forming a protective environ-
ment. The mechanism by which DNA methylation
influences susceptibility to DNA damage and sub-
sequent repair remains to be determined.
Using an in vitro model of radiation response
with LNCaP (radiosensitive) and PC-3 (radioresis-
tant) prostate cancer cell lines, we have previously
established a role for opposing regulation of DNA
repair pathways, and in particular homologous
recombination, at the transcriptional level in pros-
tate cancer cells with opposing response to RT
[13]. A question that remains is whether cells
utilized in this model exhibit an epigenetic
response to this treatment. In this study, DNA
damage, repair and DNA methylation changes
were profiled prior to and following induction of
DSBs in prostate cancer cell lines with varying
sensitivities to DNA damage. Our analysis demon-
strates that DNA methylation remains largely
unchanged following a single dose of RT with the
exception of a very small number of sites. We also
reveal that treatment with a DNA hypomethylat-
ing agent delays recruitment of the active BRCA1
DNA repair enzyme and recovery from DNA
damage.
Results
Cells with divergent response to radiotherapy
display distinct basal DNA methylation profiles
To evaluate how RT may influence the epigenome,
DNA methylation profiles of prostate cancer cells
were determined using the Illumina Infinium
HumanMethylation450 BeadChip platform
(Illumina HM450K arrays). DNA was extracted
from untreated cells at 1 or 14 d following
a single radiation dose (2 Gray (Gy)) to determine
both short-term response and more stable
changes. Included in this analysis were LNCaP,
22Rv1 and PC-3 cells, derived from a lymph
node metastasis, primary prostate tumour and
bone metastatic disease, respectively. We have
shown that these cell lines vary in terms of radio-
response with the LNCaP cells being radiosensi-
tive, the 22Rv1 cells displaying intermediate
radioresponse and the PC-3 cells being radioresis-
tant ([13], Supplementary Figure 1) as demon-
strated using clonogenic assays. At these doses of
radiation induction of apoptosis was observed,
however there was no significant difference
between cell lines (Supplementary Figure 2). Beta
(β) values were used to measure levels of DNA
methylation, these range from 0 to 1, with 0 repre-
senting unmethylated CpGs and 1 representing
fully methylated CpGs. Analyses indicated distinct
DNA methylation patterns between the three cell
lines. Overall, PC-3 cells had a larger proportion of
hypermethylated probes as determined by β
values, compared to the LNCaP and 22Rv1 cells
(Figure 1(a,b)). Hierarchical clustering based on
methylated probes resulted in each cell line clus-
tering distinctly from each other (Figure 1(c)) with
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Figure 1. Methylation profiles of LNCaP, 22Rv1 and PC-3 cell lines before and after radiotherapy. Prostate cancer cell lines were
exposed to 2 Gy radiation and DNA was extracted at 0, 1 and 14 d. DNA methylation was profiled using the Illumina Infinium
HM450K platform. (a) Density distribution of β values for the LNCaP, 22Rv1 and PC-3 cell lines. (b) β value distribution for the three
cell lines and time-points. (c) Sample relatedness ranked according to methylation status across the cell lines and time-points.
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the methylation profiles obtained for the more
radiosensitive 22Rv1 and LNCaP cells being more
closely related than the radioresistant PC-3
methylome.
DNA methylation stability in prostate cancer cells
following radiotherapy
Following from the analysis of basal DNA methyla-
tion profiles in the three cell lines, we next sought to
determine how DNA methylation may be altered by
exposure to RT. DNA methylation profiles of
untreated cells versus those exposed to RT were
compared. Overall, DNA methylation was found to
be largely unchanged by RT treatment. However,
a number of CpG sites had a > 0.25 change in β
value over the time course of treatment (Figure 2(a))
with 39 altered CpG sites detected in the LNCaP
cells, 33 in the 22Rv1 cells and 35 in the PC-3 cell
line. This represents approximately 0.01% of the
HM450K array coverage, and these CpG sites were
random in terms of distribution being detected
across numerous chromosomes and located in gene
bodies, promoters, transcription start sites and 5ʹ
UTRs. While a small portion of these CpG sites
became hypomethylated by day 14 post RT, the
vast majority displayed increased DNA methylation
(Figure 2(a)). Two CpG sites were altered in
response to RT in more than one cell line; ZMIZ1
(cg14371731) in LNCaP and PC-3 cells and
HOXA11 (cg27309564) in the LNCaP and 22Rv1
cell lines. Interestingly methylation at these sites
did not follow the same pattern of change for each
cell line over the time course.
HOXA11 methylation has previously been iden-
tified as a potential predictive marker for poor
outcomes in acute myeloid leukaemia (AML) and
ovarian cancer [14,15] and was found to have
altered DNA methylation following a single dose
of RT in both LNCaP and 22Rv1 cells. 22Rv1 cells
were chosen for validation as this cell line is
derived from the primary tumour, which is the
site receiving RT and is therefore most clinically
relevant. In the 22Rv1 cells, the β values for 0, 1
and 14 d for the HOXA11 cg27309564 probe were
0.228, 0.487 and 0.609, respectively, indicating an
increase in methylation over the time course. To
validate this data, DNA from non-irradiated and
irradiated 22Rv1 cells was subject to bisulphite
conversion and examined by clonal sequencing
across the HOXA11 gene body (Figure 2(b)). The
increased methylation evident at this HOXA11 site
following RT uncovered by the arrays was
reflected in the methylation profile observed by
clonal bisulphite sequencing.
No differences in susceptibility to DNA damage
were detected between sensitive and resistant
prostate cancer cells
While the Illumina HM450K array data indicated
that each cell line had a distinct DNA methylation
profile, it was unclear as to whether this may
reflect inherent differences in their susceptibility
to DNA damage. To determine whether there were
innate differences in sensitivity to DNA damage
between cell lines, the cell lines with the two
extremes of RT response, LNCaP (radiosensitive)
and PC-3 (radioresistant) cells were treated with
the radiomimetic phleomycin to induce DSBs.
This compound generates DSBs similar to those
induced by ionizing radiation via a free-radical
driven process [16]. Following treatment, cells
were allowed to recover for 10 min, 30 min, 1
h or 2 h before undergoing γH2A.X immunofluor-
escence staining. PC-3 cells displayed an average
of 4 γH2A.X foci per cell with reduced numbers of
foci at baseline in LNCaP cells, averaging 2 foci
per cell (Figure 3(a)), although this difference was
not statistically significant (P = 0.119). Next, we
profiled the extent of DNA damage and recovery
in these cells, by determining the resolution of
γH2A.X foci following DNA damage. PC-3
(Figure 3(b)) and LNCaP cells (Figure 3(c)) dis-
played a similar trend with γH2A.X foci increasing
during the 2-h recovery period. While these
changes were not significant for the PC-3 cells (P
= 0.063), LNCaP cells displayed a significant
increase in foci over the time course (P = 0.008).
Interestingly the radioresistant PC-3 cells consis-
tently displayed a higher number of foci than the
LNCaP cells. Untreated PC-3 cells averaged 4 foci
per cell, increasing to an average of 18 foci per cell
2 h following DNA damage (Figure 3(b)). LNCaP
cells averaged 2 foci per cell when untreated and
by 2 h following exposure to phleomycin, this had
increased to an average of 11 foci per cell.
However, the differences in foci numbers between
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Figure 2. Methylation changes following radiotherapy in LNCaP, 22Rv1 and PC-3 cells. Prostate cancer cell lines were exposed to 2 Gy
radiation and DNA was extracted at 0, 1 and 14 d. DNAmethylation was profiled using the Illumina Infinium HM450K platform. (a) Heatmaps
(generated using Morpheus https://software.broadinstitute.org/morpheus/) based on β values of differentially methylated regions post-
radiotherapy in LNCaP, 22Rv1 and PC-3 prostate cancer cells at 0, 1 and 14 d. β values range from 0 to 1 with 0 being unmethylated (blue) and
1 being 100%methylated (red). (b) Bisulphite sequencing validation of methylation for the HOXA11 gene body for six clones (Illumina probe
cg27309564 spans last three CpGs highlighted in box) in 22Rv1 cells. White circles represent unmethylated CpGs and black circles represent
methylated CpGs.
EPIGENETICS 5
the cell lines were not significant. Using the pro-
longed presence of γH2A.X foci as an indirect
marker for damage recovery, these data demon-
strated that the LNCaP and PC-3 cells responded
to damage in a similar manner within a 2-h time
frame. In addition, the PC-3 cells (radioresistant
cell line) appear to experience slightly higher levels
of initial DNA damage compared to the LNCaP
cells (radiosensitive) under the same treatment.
Treatment with 5-azacytidine delays DNA repair
in PC-3 cells
While the prostate cancer cell lines displayed distinct
basal DNA methylation profiles, there were limited
differences in terms of changes to DNA methylation
following RT and their inherent susceptibility to DNA
damage. The role of DNA methylation in the DNA
damage response was therefore further investigated
by attempting to reduce the levels of DNA methyla-
tion in the PC-3 cells, which are more resistant to
DNA damage [13] and displayed higher levels of basal
DNA methylation (Figure 1). A number of previous
studies have demonstrated the sensitizing capabilities
of the demethylating agent 5-AzaC which has been
shown to increase cell death [9,10,17]. In order to
assess whether decreasing global DNA methylation
could augment DNA damage and cell death in
response to the radiomimetic, PC-3 cells were treated
with 5-AzaC prior to DSB induction. Survival was
profiled via clonogenic assay comparing untreated
cells to those pre-treated with 5-AzaC before exposure
to phleomycin. No significant difference in colony
formation was observed between cells treated with
phleomycin alone and cells pre-conditioned with
5-AzaC before phleomycin treatment (Figure 4(a)).
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Figure 3. Basal susceptibility to DNA damage and DNA damage recovery in sensitive and resistant prostate cancer cell lines. PC-3
and LNCaP cells were grown on chamber slides and exposed to phleomycin for 1 h and left to recover for the indicated times. Cells
were then probed for γH2A.X foci via immunofluorescence staining and the average number of foci for 100 cells determined. (a)
Basal levels of DNA damage in LNCaP cells and PC-3 cells. (b) Foci counts for PC-3 cells following phleomycin recovery. (c) Foci
counts for LNCaP cells following phleomycin recovery. The experiments were performed in triplicate and the average number of foci
for 100 cells determined. The mean and SEM for three biological replicates are shown. Statistical significance was determined using
Student’s t Test (a) or One-way ANOVA (b & c) *P < 0.05.
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This suggests that 5-AzaC did not alter the survival of
prostate cancer cells following DNA damage.
Reduced DNA methylation in the 5-AzaC-treated
cells was confirmed by methylation-sensitive restric-
tion digestion (data not shown). Next, we measured
the number of γH2A.X foci in cells treated with or
without the DNA hypomethylating agent in combi-
nation with phleomycin. While PC-3 cells treated
with 5-AzaC exhibited a lower number of γH2A.X
foci at 2 h, by 24 h the number of foci was significantly
higher in comparison to the control cells (P = 0.0143,
Figure 4(b) and γH2A.X panels in Figure 4(c)).
DNA methylation is maintained by DNMT1
which has previously been demonstrated as
being recruited to DSBs [18], therefore we
were interested in determining how recruitment
of this enzyme was influenced by treatment of
cells with 5-AzaC prior to DSB induction.
Using immunofluorescence staining it was
found that nuclear DNMT1 levels appear higher
while DSBs are present. While there is some co-
localization evident, the enzyme does not
appear to completely co-localize with the DSBs
(Figure 4(c)). More punctate DNMT1 staining
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Figure 4. Influence of 5-AzaC on cell survival and DNA repair. PC-3 cells were either pre-treated with 5-AzaC or left untreated, then
treated with phleomycin for 1 h and left to recover. (a) Clonogenic assay showing cell survival with or without 5-AzaC pre-treatment.
The mean and SEM for three biological replicates are shown. (b) Average foci counts for γH2A.X staining. The mean and SEM for
three biological replicates are shown. Statistical significance was determined using Two-way ANOVA, *P < 0.01. (c) Representative
example for immunofluorescence staining of DNMT1 and γH2A.X in cells treated with or without 5-AzaC prior to phleomycin
addition.
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is seen in cells with DNA damage as opposed to
those which have undergone repair (24-h post-
treatment with phleomycin).
5-azacytidine treatment delays BRCA1
recruitment to DSBs
The delayed resolution of γH2A.X foci observed in
cells treated with 5-AzaC might indicate an
impaired DNA repair response. Previously we
have shown that BRCA1 is transcriptionally up-
regulated following a single dose of RT in PC-3
cells [13] therefore we investigated how BRCA1
recruitment may be influenced by DNA hypo-
methylation in the presence of 5-AzaC. BRCA1
phosphorylated at serine 1423 (p-BRCA1) was
analysed as this modification occurs in response
to DNA damage and has previously been asso-
ciated with radiation sensitivity [19]. PC-3 cells
treated with phleomycin alone exhibited numerous
γH2A.X foci at 2-h post-exposure, with nuclear
p-BRCA1 also being detected in these cells
(Figure 5). Control cells had resolved γH2AX
foci by 24 h and p-BRCA1 was not detected at
this time point (Figure 5). In contrast, cells that
had been treated with 5-AzaC prior to phleomycin
treatment had high levels of DSBs at 2 h as
reflected by γH2A.X foci levels however the corre-
sponding increase in p-BRCA1 was not evident.
Cells treated with 5-AzaC failed to resolve the
γH2A.X foci by 24 h compared to the control.
While p-BRCA1 was not detected at 2 h, it was
detected at 24 h in these cells as evidenced by the
punctate staining in the nucleus and cytoplasm.
These data demonstrate that 5-AzaC treatment is
associated with a delay in p-BRCA1 recruitment to
DSBs and a delayed recovery from DNA damage.
Discussion
One of the great challenges in cancer treatment is
the individual variation in response to therapy.
Identifying the key drivers of treatment resistance
is integral in addressing this problem and in tai-
loring treatment. It is becoming increasingly evi-
dent that the epigenetic profile of cancer cells can
impact response to therapy (reviewed in [20]). By
understanding adaptations that enable cancer cell
survival against various treatment modalities, we
can provide insight into the mechanisms of treat-
ment resistance. Using prostate cancer cells with
varying sensitivities to radiation-induced DNA
damage, we sought to investigate how basal DNA
methylation might influence response to treatment
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2 hour recovery 
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24 hour recovery 
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Figure 5. Influence of 5-AzaC on BRCA1 recruitment and DNA repair. PC-3 cells were grown on chamber slides, either pre-treated
with 5-azacytidine or left untreated, then treated with phleomycin for 1 h and left to recover for 2 or 24 h. Cells were then fixed and
probed for p-BRCA1 (ser1423) and γH2A.X via immunofluorescence staining.
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and how DNA methylation may be altered follow-
ing DNA damage.
The data presented here show that each prostate
cancer cell line displayed a distinct basal methyla-
tion profile. The radioresistant PC-3 cells exhibited
higher levels of overall DNA methylation. There is
evidence that increased CpG methylation is corre-
lated with radioresistance. For example, radiation
resistant head and neck squamous cell carcinoma
cell lines have increased CpG methylation [21]
which is in agreement with our findings.
Supporting the translational relevance for these
findings, Chen et al. [21] also demonstrated that
radiation resistant head and neck cancer patient
samples had increased CpG hypermethylation.
The increased DNA methylation observed in the
PC-3 cells however, does not appear to influence
susceptibility to DNA damage as PC-3 and LNCaP
cells displayed similar levels of γH2A.X foci fol-
lowing phleomycin-induced DNA damage. In fact,
the PC-3 cells showed slightly higher basal levels of
DNA damage than the LNCaP cells, indicating
that the level of initial DNA damage does not
determine cell survival. Instead, the variation in
sensitivity to DNA damage in these cells may
potentially be attributed to the efficacy of the sub-
sequent DNA repair process. Alternatively,
increased levels of DSBs may enhance the devel-
opment of therapy-resistant clones via increased
mutations and rapid genetic evolution. Both of
these potential mechanisms warrant further inves-
tigation. It should be noted that while this immu-
nofluorescence data provide valuable insight into
the levels of DSBs in each cell line, the resolution
of γH2A.X staining does not reflect 100% of the
DSBs within the cell.
The random and transient nature of DSB induc-
tionmeans it is difficult to pinpoint and capture their
corresponding epigenetic impact, here the coverage
enabled by the Illumina Infinium HM450K array
platform has provided insight on a finer scale.
DNA damage induced by RT occurs at a higher
frequency in regions of euchromatin and actively
transcribed regions [22,23]. The HM450K probes
are biased towards active promoter regions and
these potential DNA damage hotspots. Overall,
while very few changes in methylation were detected
in response to RT, these indicate that subtle heritable
changes in the epigenetic profile of cells exposed to
DNA damaging agents are possible and may corre-
late with the sites of DSB repair. A limited number of
localized DNA methylation changes are more likely
than large genome-wide changes due to localized
repair activity resulting in modifications to the site
immediately surrounding the repaired DSB. A dose
of 1 Gy would be expected to generate approximately
40 DSB lesions per cell [24]. Our data identified
between 33 and 39 CpG sites altered in the three
cell lines following a dose of 2 Gy which represents
about half the expected number of DSBs. However,
the HM450K arrays cover less than 2% of all CpGs so
there are many potential-impacted sites undetected
in this analysis. A similar study by Antwih et al. [25]
investigated methylation changes in MDA-MB-231
breast cancer cells before and after RT. They demon-
strated hundreds of genes which were hyper or
hypomethylated following RT and a subset of these
were functionally relevant, being involved in DNA
repair, apoptosis and cell cycle regulation.
Numerous CpG sites displayed altered β values
up to 14 d following exposure to 2 Gy, providing
evidence for stable changes to DNA methylation
following a single dose of RT. This is supported by
the findings of O’Hagan et al. [4], with DSB repair
in an exogenous promoter model revealing long-
term heritable gene silencing and indicating an
‘epigenetic memory’ of the DSB event and its sub-
sequent repair. Similarly, repair of I-SceI restric-
tion enzyme-induced DSBs driven by homologous
recombination has been shown to trigger increased
DNA methylation [6]. Our data provide evidence
for stable alterations to the epigenome in response
to a single dose of RT which could potentially
influence future response to treatment. The cumu-
lative impact of localized DNA methylation
changes following repeated DNA damage there-
fore needs to be determined. Ideally, to further
characterize epigenetic adaptations to DNA
damage, future work should focus on inducing
DSBs at specific sites (perhaps using CRISPR/
Cas9) within a chromatin context prior to DNA
methylation profiling along with investigating
other epigenetic alterations such as histone mod-
ifications and miRNAs.
The CpG sites identified as having altered
methylation following RT may hold some predic-
tive value, in fact ZMIZ1 promoter methylation
has been patented for treatment selection and
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predicting improved patient survival in a range of
cancers [26]., with reduced ZMIZ1 expression
associated with improved patient outcomes. In
addition, HOXA11 methylation has been used to
predict survival outcomes for AML patients [14]
and identified as a potential prognostic biomarker
for ovarian cancer patients, with HOXA11 promo-
ter methylation predicting poor outcomes in ovar-
ian cancer [15]. Reduced expression of HOXA11
has also been linked to treatment resistance in
glioblastoma, including RT [27]. These two CpGs
located within the HOXA11 and ZMIZ1 gene
bodies appear to be susceptible to DNA methyla-
tion changes in more than one cell line, indicating
that they may be hotspots for DNA damage.
The DNA methylation inhibitor, 5-AzaC has
shown promise as a DNA damage sensitizing
agent, however the numerous cellular impacts of
this DNAmethylation inhibitor complicate and con-
found results. Pre-treating PC-3 cells with 5-AzaC
did not sensitize them to DNA damage as some
previous studies have shown [9,10,17]. This may be
due to the cellular context and differences in the
inherent methylation profiles between different cell
lines. In addition, sensitization by 5-AzaC may be
modulated via its effects on transcription, RNA
methylation (reviewed in [28]), DSB induction
[29,30], histone modifications [31,32] or via trigger-
ing interferon and viral defence pathways [33]. It can
also impact the localized recruitment of DNMT1
which has been shown to be recruited to sites of
DNA repair [34]. These factors could all potentially
influence the DNA damage response and play
a further confounding role in sensitization, demon-
strating that the role for these inhibitors is certainly
not clear cut.
While 5-AzaC did not sensitize prostate cancer
cells to DNA damage, our immunofluorescence data
demonstrated that 5-AzaC treatment delays recovery
fromDNAdamage. Stalled DNA repair could poten-
tially be attributed to the decrease in DNA methyla-
tion influencing signalling events required for
recruiting DNA repair machinery or perhaps altered
transcriptional programs are defective in managing
protein levels required for the DNA damage
response. DNMT1 trapping by 5-AzaC treatment
may also be a key factor for this delay in DNA repair.
A reduction in DNMT1 activity has previously been
shown to inhibit the rate of DNA repair and 5-AzaC
treatment has been shown to prevent DNMT1
recruitment to DSBs [18]. Alternatively, the delay
in recovery from DNA damage may be attributed
to another cellular process influenced by 5-AzaC as
mentioned previously. Our immunofluorescence
data also revealed diffuse staining of DNMT1 in
the absence of DNA damage, with more punctate
staining evident in cells involved in repairing DSBs.
This observation adds further support for the role of
DNMT1 in DNA repair [4,18,34].
In summary, our data provide evidence for stable
epigenetic changes from a single dose of RT which
has significant clinical implications in terms of
cumulative effects of fractionated dosing regimens.
While DNA methylation profiles in prostate cancer
cells with divergent response to RT were stable on
a genome-wide scale following a single dose of RT,
a small subset of genes displayed altered CpGmethy-
lation following treatment. The sites identified
exhibited a tendency towards gaining methylation
and may represent regions of DSB repair. The ran-
dom and transient nature of DSB induction and
repair makes studying the epigenetic status at speci-
fic sites difficult however the advent of methylation
arrays has enabled snapshots to be captured. Our
data demonstrate that prostate cancer cells with
a varied response to DNA damage have distinctive
DNAmethylomes. However, while the resistant cells
generally exhibited higher levels of DNA methyla-
tion this did not influence susceptibility to DNA
damage or the rate of short-term repair. In terms of
clinical relevance, DNA methylation may have the
potential to serve as a powerful biomarker of ther-
apeutic response however the complexity of DNA
repair within a chromatin context must be resolved.
These heritable changes have the potential to influ-
ence not only the transcriptional profile of the cell
but also future response to treatment. Clearly defin-
ing the interactions between the epigenome and
DNA repair will only prove to strengthen our under-
standing of an individual’s tumour sensitivity and
treatment efficacy.
Materials and methods
Cell culture and treatments
LNCaP and 22Rv1 cells were cultured in RPMI med-
ium while PC-3 cells were cultured in HAMSF12K.
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All media were supplemented with 10% FBS
(Bovogen SFBSA3) and 5000 U/ml Penicillin and
5000 μg/ml Streptomycin (Gibco 15070063). Cells
were irradiated as previously described [13]. The
radiomimetic, phleomycin (Sapphire Biosciences
15549) was used at a final concentration of 50μg/ml
for 1 h, before medium was removed, washed with
PBS and replaced with fresh medium. Cells were then
left to recover for the indicated time points. Cells were
treated with 0.3 μM 5-azacytidine (5-AzaC, Sigma
Aldrich A2385) or vehicle for 24 h, following which
medium was aspirated and replaced with fresh med-
ium. Cells were left to divide for a further 24 h before
inducing DNA damage.
Illumina HM450K array sample preparation
DNA was extracted from cells recovering from 2 Gy
irradiation at indicated time points using the Qiagen
DNeasy kit. Illumina HM450K BeadChips were per-
formed by the Australian Genome Research Facility.
Illumina HM450K array data processing
Raw signal intensity was imported into R (v 3.2) and
processed using the minfi R package. Raw data
underwent the standard Illumina normalization
and SWAN [35]. Individual probes with detection
p-value higher than 0.05 were considered unreliable
and removed from the analysis. In total, β
and M values were calculated from 484,330 probes.
To examine overall methylation similarities and dis-
similarities, a density plot was generated using β-
value and a hierarchical clustering using M-value.
Heatmaps were generated using Morpheus (https://
software.broadinstitute.org/morpheus/) based on β
values of differentially methylated CpGs.
Bisulphite sequencing
Bisulphite sequencing was carried out as pre-
viously described [36] using HOXA11 primers
For: GAAAGTAGTTAAGTGGGGGTTGT, Rev:
AACCAAAACTCAAACTAACAAAAAC.
Immunofluorescence assay
Cells were seeded onto Lab-Tek II eight-well cham-
ber slides (Thermo Fisher Scientific) and treated
with the appropriate agents before washing in
warm PBS. Cells were then fixed using 4%
Paraformaldehyde (Life Technologies 28906) for 10
min at room temperature. Fixed cells were then
washed in PBS and permeabilized in 0.1% Triton-
X. Cells were washed in PBS prior to blocking for 1
h at room temperature with shaking in blocking
buffer (0.1% Tween-20 + 5% FCS) then incubated
with the appropriate primary antibody (DNMT1
(SigmaAldrich D4567) used 1:100, BRCA1 phospho
S1423 (Abcam ab47325) used at 1 μg/ml and γH2A.
X [3F2] (Abcam ab22551) used at 3 μg/ml) overnight
at 4°C. After washing each chamber in blocking
buffer, the corresponding secondary antibody was
added, the chamber slide wrapped in foil and incu-
bated at room temperature for 1 h. Each well was
then washed with PBS. The chamber apparatus was
removed and DAPI/Fluroshield (Abcam ab104139)
was added to the slide. After coverslipping and seal-
ing, slides were stored in the dark at 4°C prior to
imaging. Images were captured on the Andor
Spinning Disk Confocal Microscope. FITC was cap-
tured at an exposure time of 200 ms, Alexa Fluor at
100 ms and DAPI at 100 ms.
Image analysis in Fiji Image Analysis software
Immunofluorescence images were analysed using
Fiji Image Analysis software. Cells were isolated by
firstmaking the image binary and then using the find
maxima function to localize the foci. Integrated den-
sity analysis was used to determine the number of
foci for each cell. Results were generated in a table
and copied to Microsoft Excel. After performing
counts for 100 cells, the number of foci per cell was
averaged and graphed in GraphPad Prism (Prism
version 5.03 for Windows, GraphPad Software, La
Jolla California USA, www.graphpad.com). P-values
were calculated via Student’s t-test to determine sta-
tistical significance of differences between cell lines.
One-way repeated measures ANOVA and Tukey’s
post-test were used to determine statistical signifi-
cance between treatments.
Clonogenic assay
Clonogenic assays were performed as previously
described [13]. Briefly, PC-3 cells were seeded at 1 ×
103 cells per well and either left untreated or treated
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with 5-AzaC before phleomycin treatment at 1, 10, 50
or 100 μg/ml. After 14 d, colonies were fixed with 3:1
methanol to glacial acetic acid for 5 min. Following
this, the fixative agent was removed, wells air dried
completely and cells were stained with 1.0% methy-
lene blue (Sigma-Aldrich, USA) in 50% ethanol for 30
min. Percentage of cell survival was calculated as the
number of colonies post-treatment relative to the
number of colonies within the corresponding control.
Annexin and propidium iodide staining
Apoptosis and necrosis were detected using the Alexa
Fluor® 488 annexin V/Dead Cell Apoptosis Kit
(Invitrogen, USA). Cells were analysed by flow cyto-
metry using the FACSCantoTM Flow Cytometer (BD
Biosciences, USA). PMT voltages were adjusted so
negative control cells were within the first two log
decades of the fluorescent parameter. Positively
stained cell populations were discriminated on the
basis of Alexa Fluor® 488 annexin V and PI control
samples.
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